Literature DB >> 1616326

Risk factors in the pregnancy of patients with systemic lupus erythematosus: association of hypocomplementaemia with poor prognosis.

S Shibata1, T Sasaki, Y Hirabayashi, J Seino, K Okamura, K Yoshinaga, N Morito, R Kasukawa, S Aotuka, R Yokohari.   

Abstract

Fetal wastage is still high in the pregnancies of patients with systemic lupus erythematosus (SLE). We examined retrospectively the cases of 38 patients with inactive SLE in whom pregnancy was either desired or had already been obtained. The prevalence of antiphospholipid antibodies in the group with fetal loss was high. The antibodies were, however, also detected in five of 14 patients who had had a live birth. It was noted that low levels of serum complement activity (CH50 less than 25 U/ml) occurred in five of six patients with fetal loss, but in only two of 22 with a live birth. Serial studies also confirmed a close association between decreased serum complement activity and poor fetal prognosis in lupus pregnancy. Treatment with increased doses of prednisolone may help to achieve successful live births. Thus hypocomplementaemia may be associated with a worse prognosis for the fetus in the pregnancies of some patients with SLE in remission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616326      PMCID: PMC1005693          DOI: 10.1136/ard.51.5.619

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  The anticardiolipin syndrome.

Authors:  G R Hughes; N N Harris; A E Gharavi
Journal:  J Rheumatol       Date:  1986-06       Impact factor: 4.666

Review 2.  Anti-phospholipid antibodies.

Authors:  E N Harris; A E Gharavi; G R Hughes
Journal:  Clin Rheum Dis       Date:  1985-12

Review 3.  Lupus pregnancy.

Authors:  M D Lockshin
Journal:  Clin Rheum Dis       Date:  1985-12

4.  Serum complement levels and perinatal outcome in pregnancies complicated by systemic lupus erythematosus.

Authors:  L D Devoe; G L Loy
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

5.  Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion.

Authors:  A M Unander; R Norberg; L Hahn; L Arfors
Journal:  Am J Obstet Gynecol       Date:  1987-01       Impact factor: 8.661

6.  Hazards of lupus pregnancy.

Authors:  M D Lockshin; T Qamar; M L Druzin
Journal:  J Rheumatol Suppl       Date:  1987-06

7.  Fetal survival after prednisone suppression of maternal lupus-anticoagulant.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

8.  Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.

Authors:  M H Liang; S A Socher; M G Larson; P H Schur
Journal:  Arthritis Rheum       Date:  1989-09

9.  Systemic lupus erythematosus in pregnancy.

Authors: 
Journal:  Ann Intern Med       Date:  1981-05       Impact factor: 25.391

10.  Lupus pregnancy. Case-control prospective study demonstrating absence of lupus exacerbation during or after pregnancy.

Authors:  M D Lockshin; E Reinitz; M L Druzin; M Murrman; D Estes
Journal:  Am J Med       Date:  1984-11       Impact factor: 4.965

View more
  3 in total

1.  Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre.

Authors:  D L Huong; B Wechsler; D Vauthier-Brouzes; H Beaufils; G Lefebvre; J C Piette
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  Pregnancy outcomes in Japanese patients with SLE: retrospective review of 55 pregnancies at a university hospital.

Authors:  Haruko Ideguchi; Shigeru Ohno; Takeaki Uehara; Yoshiaki Ishigatsubo
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

3.  EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.

Authors:  L Andreoli; G K Bertsias; N Agmon-Levin; S Brown; R Cervera; N Costedoat-Chalumeau; A Doria; R Fischer-Betz; F Forger; M F Moraes-Fontes; M Khamashta; J King; A Lojacono; F Marchiori; P L Meroni; M Mosca; M Motta; M Ostensen; C Pamfil; L Raio; M Schneider; E Svenungsson; M Tektonidou; S Yavuz; D Boumpas; A Tincani
Journal:  Ann Rheum Dis       Date:  2016-07-25       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.